|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||8.35 - 8.35|
|52 Week Range||2.97 - 8.36|
|Beta (3Y Monthly)||2.92|
|PE Ratio (TTM)||69.01|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
One of the biggest catalysts for a cannabis stock is 2019 is to uplist to a major stock exchange. OrganiGram (OGRMF) is the next company in that line causing the stock to reach new highs.NASDAQ Uplisting After the closing bell today, OrganiGram's stock will uplist to the Nasdaq Global Select Market, and the symbol will be changed from “OGRMF” to “OGI.”On the news, the stock is trading above $8 to a market cap of $1.3 billion. Investors clearly jumped into the stock following the announcement that the company filed an application to uplist back on April 26 when the stock was trading closer to $6.50.The stock has more than doubled from the lows back in December. As some of the large Canadian players struggle with lofty valuation premiums after those stocks went public or uplisted to major stock exchanges last year, the smaller players are outperforming on the greater liquidity and stock recognition from being on the Nasdaq or NYSE.Strong FQ2 ResultsThe uplisting news comes on the heels of OrganiGram posting strong FQ2 results last month. For the quarter ended February 28, the cannabis company posted revenues of C$26.9 million that doubled the prior quarter.The Canadian company has made a focus on the adult-use market and the results are shining. As opposed to some larger players chasing global expansion and consumables market that aren’t even open yet, OrganiGram is focused on producing in the Canadian markets that are already open for business.For the quarter, the company generated an impressive adjusted EBITDA of C$13.3 million for a margin of 49%. OrganiGram achieved this target by refraining from wild expenses with SG&A costs that included stock-based compensation at only 21% of net revenues. As well, cultivation costs were a minimal $0.85 per gram of dried flower harvested.Another great part of the story is that the company is perfectly positioned to reach production targets of 113,000 kg by the end of 2019. The best part of the expansion plans are that OrganiGram isn’t aggressively trying to supply the world with cannabis, but the company is still tripling expansion in order to meet demand growth as the Canadian market slowly shifts from illegal to legal sources.The additional Phase 5 expansion will provide the company with the ability to enter the derivatives and edibles market as it opens up later this year. Vape pens and edibles offer some promising high-margin revenue sources as 2019 ends.TakeawayThe key investor takeaway is that these under the radar cannabis stocks uplisting to major stock exchanges are providing the best opportunities in the current market climate. With annualized revenues topping $100 million in the last quarter prior to further expansion and the stock trading at only $1.3 billion, OrganiGram provides an appealing valuation. A quick stock pop next week to $10 would only yield a market valuation of $1.7 billion.The best part of the story is the cost focus in the competitive market. OrganiGram isn’t wildly spending on bleeding edge expansion plans while still taking advantage of the growth opportunities in the Canadian cannabis market.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. Disclosure: The author has no positions in OrganiGram stock. More recent articles from Smarter Analyst: * A Look at Qualcomm (QCOM)-FTC Outcome and Its Impact on Apple (AAPL) * It's Time to Cut Estimates for Tesla (TSLA); Stock Remains a Long-Term Opportunity * Cannabis Stock Pick of the Week: Zenabis Global * Will Qualcomm (QCOM) Stock Price Get Back to $60-65? Not So Sure
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations NEW YORK , May 17, 2019 /PRNewswire/ -- Virtual Investor Conferences, ...
MONCTON , May 17, 2019 /CNW/ - Organigram Holdings Inc. (TSX VENTURE: OGI) (OGRMF), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce that its common shares will commence trading on the Nasdaq Global Select Market under the symbol "OGI" on Tuesday May 21, 2019 . Organigram's common shares will continue to be listed and trade on the Toronto Venture Exchange (TSXV), also under the symbol "OGI".
MONCTON, NB , May 13, 2019 /CNW/ - Organigram Holdings Inc. (TSX VENTURE: OGI) (OGRMF), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis is pleased to announce the recent appointment of government relations expert Cameron Bishop as the Company's Vice President, Public Affairs and Stakeholder Relations ( North America ).
OrganiGram: Analysts' Ratings and Target Price(Continued from Prior Part)ValuationsLately, cannabis stocks have seen a lot of pessimism. Some of the stocks are trading in the “oversold” territory. OrganiGram (OGRMF) has delivered gains since
OrganiGram: Analysts' Ratings and Target PriceOrganiGram updateOn April 15, OrganiGram (OGRMF) reported its second-quarter earnings with sales of 34.9 million Canadian dollars—compared to 3.7 million Canadian dollars in the same quarter the
NEW YORK , May 6, 2019 /PRNewswire/ -- CannaStocks2019 today announced that its Q1 Investor Conference will be held at the OTC Markets Group offices in New York on May 15 th . Participating companies ...
Cannabis Sector Extended Its Losses Last WeekCannabis sector weakenedIn the week ending May 3, the cannabis sector extended its weakness. Most of the stocks ended in the negative territory. The Horizons Marijuana Life Sciences ETF (HMMJ) lost
Midday Update: How Cannabis Stocks Are Holding Up on May 3Cannabis stocks riseThe cannabis sector was on the rise in the first half of the day on May 3 after some major cannabis stocks received rating changes from Jefferies in the early morning.
OrganiGram Holdings (OTCMKTS:OGRMF) is a Canadian company that grows and sells medical marijuana. Its products include various strains, oils, and even vaporizers. Despite being a pot stock, I like this company and am considering buying some shares. Because, unlike most marijuana stocks, OrganiGram actually makes money!Source: Shutterstock As you are well aware, there is a frenzy occurring in the legal cannabis markets. You can't turn on the news or surf the web without coming across numerous stories about the marijuana industry. But it is important to understand that most of the cannabis companies are losing money and have no real future prospects.Consider all of the companies that are trading for fractions of a penny. Most of these companies will eventually become unable to raise cash to run their businesses. They will be bankrupt.InvestorPlace - Stock Market News, Stock Advice & Trading TipsEven well-known companies like Tilray (NYSE:TLRY) and General Cannabis (OTCMKTS:CANN) are losing money. * 7 Stocks That Are Soaring This Earnings Season This type of phenomenon is not new. It has occurred many times throughout history when an innovative new industry is formed. For example, when cars were invented there were soon over 300 companies that produced them. Eventually, there were three. The same type of consolidation happened in the internet boom. Click to Enlarge OrganiGram's profit trend is headed in the right direction. In 2014, the company lost 52 cents per share and in 2015 it lost 2 cents per share. 2016 was a breakeven year and in 2017 the loss was 11 cents per share. Last year, Organigram became profitable and reported earnings of 17 cents per share.Analysts estimate that OrganiGram will earn even more than that this year. The average estimate is 24 cents and the average price target is $11.65.To learn more about OrganiGram and other things happening in the Cannabis markets please check out this week's Kronical: More From InvestorPlace * 7 A-Rated Stocks That Are Under $10 * 7 Stocks That Are Soaring This Earnings Season * 5 Biotech Stocks for a Long-Lived Portfolio * 10 Times Apple's Hardware Failed Consumers -- And Hurt Its Business Compare Brokers The post Unlike Most Cannabis Stocks, This One Actually Makes Money appeared first on InvestorPlace.
Organigram Holdings Inc. sold the second-most amount of recreational cannabis in Canada, but its market capitalization trails rivals handily — at least until it lists on the Nasdaq and gets access to more institutional investors.
Valuation in the Cannabis Sector: An End-of-Month Update(Continued from Prior Part)Cronos GroupCronos Group’s (CRON) recent valuation has been significantly higher than its historical average and that of peers (MJ) Aurora Cannabis (ACB), Aphria
Cannabis stocks were mixed on Monday, with Aleafia Health losing ground after reporting earnings for 2018 and Organigram gaining on the news it has applied for a listing on Nasdaq.
MONCTON, NB , April 30, 2019 /CNW/ - Organigram Holdings Inc. (TSX VENTURE: OGI) (OGRMF), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis is pleased to announce that it has received an expanded cultivation license from Health Canada in line with its previously announced Phase 4A and 4B expansion plans for its Moncton Campus.
Canopy Growth Rises on New York Hemp Facility UpdateCanopy Growth risesCanopy Growth (WEED)(CGC) stock rose about 4% in the first half of April 29’s trading session after it provided an update on its hemp industrial park in New York. The company
MONCTON, NB , April 26, 2019 /CNW/ - Organigram Holdings Inc. (TSX VENTURE: OGI) (OGRMF), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that it has applied to list its common shares on the NASDAQ Global Select Market ("NASDAQ"). In advance of anticipated listing on the NASDAQ, Organigram will file a Form 40-F Registration Statement with the United States Securities and Exchange Commission. The listing of the Company's common shares on the NASDAQ remains subject to the approval of the NASDAQ and the satisfaction of all applicable listing and regulatory requirements. The Company will continue to maintain the listing of its common shares on the TSX Venture Exchange under the symbol "OGI".
CTST, TLRY, CGC, and Other Cannabis Stocks on the Rise(Continued from Prior Part)HEXO and APHA gain Today, HEXO (HEXO) was moving higher with a daily gain of 1.3% around noon while Aphria (APHA) wasn’t far behind with a gain of about 1%. When we
More than 40 international companies applied to address the assembled investors and industry experts at the Benzinga Cannabis Capital Conference, from major industry players to rapidly growing startups looking to scale in new markets. Targeting the side-effects and complications of pharmaceutical injury treatment, Copeland Biosciences produces CBD and THC topical formulations developed to provide targeted pain management and injury treatment. Founder and CEO Dr. Glenn Copeland said he experienced these side effects firsthand in his career as a sports medicine doctor.
One of the biggest surprises in the months since legalization is the diversity of the consumer base, Engel said. Another surprise: the strong demand for CBD, which Engel said OrganiGram continues to work to satisfy. The cannabis industry's growth wasn't a smooth ride and has had several headwinds, including supply challenges, Engel said.